Medicago to present at the 2008 BIO International Convention in San Diego, CA



    QUEBEC CITY, June 16 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"),
today announced that it will be presenting at the 2008 BIO International
Convention from June 17-20, 2008, at the San Diego Convention Center, San
Diego, California. Ms. Brigitte Barbeau, VP Manufacturing, will present
Medicago's unique solution for the rapid and cost effective production of
pandemic flu vaccines in a Breakout Session organized by Sanofi Pasteur
entitled, "Beyond the Bench: Protein Production Systems at an Industrial
Scale", being held on Thursday, June 19 at 10:30am PDT in Room 29B. This
session will discuss recent advances in manufacturing processes for
protein-based vaccines and therapeutics and consider the advantages they can
bring to large-scale protein production.

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

    Forward- Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release

    %SEDAR: 00023641EF




For further information:

For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Investor relations: The Equicom Group Inc., Arianna
Vanin, (514) 844-4680, avanin@equicomgroup.com

Organization Profile

Medicago Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890